科济药业-B(02171)发布公告，公司非执行董事郭炳森先生于2025年9月24日安详逝世。 ...

【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 格隆汇9月24日丨科济药业-B(02171.HK)宣布，公司非执行董事郭炳森于2025年9月24日安详逝世。 （责任编辑：董萍萍 ） ...

智通财经APP讯，科济药业-B(02171)发布公告，公司非执行董事郭炳森先生于2025年9月24日安详逝 世。 ...

科濟藥業控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2171） 董事名單及其角色及職能 CARsgen Therapeutics Holdings Limited C 有關委員會主席 謝榕剛先生 郭華清先生 獨立非執行董事 顏光美博士 周文博士 趙向可女士 1 附註： 科濟藥業控股有限公司（「本公司」）董事會（「董事會」）成員載列如下： 執行董事 李宗海博士 （主席） 王華茂博士 蔣華博士 非執行董事 M 有關委員會委員 香港，2025年9月24日 2 董事會設有三個委員會。下表載列各董事會成員在該等委員會中所擔任的職位： 審計委員會 薪酬委員會 提名及 企業管治委員會 李宗海博士 M C 王華茂博士 蔣華博士 謝榕剛先生 郭華清先生 M 顏光美博士 M M 周文博士 M C M 趙向可女士 C ...

香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 科濟藥業控股有限公司（「本公司」，連同其附屬公司及併表聯屬實體統稱「本集 團」或「科濟藥業」）董事會（「董事會」）沉痛宣佈，本公司非執行董事郭炳森先生 （「郭先生」）於二零二五年九月二十四日安詳逝世。 郭先生為本集團服務逾十載，憑藉深厚的商業洞察與卓越的企業家視野，始終為 本集團發展提供核心支撐。在本集團戰略轉型、業務攻堅、風險應對等關鍵節 點，郭先生從未缺席，其精準決策與全力賦能，多次助力集團突破發展瓶頸，為 業務穩健推進奠定重要基礎。董事會代表本集團向郭先生的家人致以最深切的哀 悼，並對郭先生長年來為本集團的傾力奉獻與寶貴貢獻，致以最誠摯的謝意與崇 高的敬意。 承董事會命 科濟藥業控股有限公司 董事長 李宗海博士 香港，2025年9月24日 CARsgen Therapeutics Holdings Limited 科濟藥業控股有限公司 （於開曼群島註冊成立的有限公司） （股份 ...

Core Viewpoint - The article discusses the promising advancements in "in vivo CAR-T" technology, which aims to make cancer treatment more accessible and affordable, potentially reducing costs to one-tenth of traditional methods and improving patient outcomes [3][4][5]. Group 1: Current Challenges in CAR-T Therapy - Traditional CAR-T therapy involves extracting a patient's T cells, modifying them in a lab, and reinfusing them, which is time-consuming (1-3 weeks) and costly (over 1 million yuan per treatment) [3][4]. - The complexity of the production process limits the widespread adoption of CAR-T technology, making it a "sky-high treatment" for ordinary people [3][4]. Group 2: Advancements in In Vivo CAR-T Technology - In vivo CAR-T technology allows for direct injection of carriers (like viruses or lipid nanoparticles) that modify T cells within the patient's body, eliminating the need for cell extraction [4]. - This method is expected to significantly reduce treatment costs and improve accessibility, with potential costs dropping to one-tenth of traditional CAR-T therapy [4][5]. - The treatment can show effects as quickly as three days after one or two intravenous injections, addressing the urgent needs of patients who cannot wait for traditional methods [4][5]. Group 3: Industry Implications - The shift towards in vivo CAR-T technology is attracting attention from both capital and industry, with multiple Chinese companies exploring this field [4]. - The maturation of in vivo CAR-T technology could lead to a future where patients receive effective cell therapy through simple injections, broadening the range of treatable diseases [5].

Group 1 - The company Zhaoli Pharmaceutical (300181.SZ) has a subsidiary, Zhaoli Innovation Medical, which holds shares in the Hong Kong innovative drug company Kexi Pharmaceutical-B (HK: 02171) [1] - Zhaoli Innovation Medical owns 28,385,012 shares of Kexi Pharmaceutical [1]

Core Viewpoint - The company announced the granting of stock options and restricted share units to incentivize employees and align their interests with the company's long-term growth and profitability [1] Group 1: Stock Options - On September 18, 2025, the company granted 6.7405 million stock options to 348 option grantees, pending acceptance by the grantees [1] - The purpose of granting stock options is to reward employees for their past contributions to the company's success and to encourage further contributions [1] Group 2: Restricted Share Units - On September 18, 2025, the company granted 1.9115 million restricted share units to 196 restricted share unit grantees, also pending acceptance [1] - The aim of granting restricted share units is to align the interests of eligible individuals with the group's interests through share ownership, thereby encouraging and retaining them for long-term growth and profitability [1]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. announced the granting of stock options and restricted share units to incentivize employees and align their interests with the company's and shareholders' best interests [1] Group 1: Stock Options - The company granted 6.7405 million stock options to 348 option grantees on September 18, 2025, pending acceptance by the grantees [1] - The purpose of granting stock options is to reward employees for their past contributions to the company's success and encourage further contributions [1] Group 2: Restricted Share Units - The company also granted 1.9115 million restricted share units to 196 grantees on September 18, 2025, which is subject to acceptance by the grantees [1] - The aim of granting restricted share units is to align the interests of eligible individuals with the group's interests, encouraging retention and contributions to long-term growth and profitability [1]

Core Viewpoint - Company Kintor Pharmaceutical Co., Ltd. (02171.HK) announced the granting of stock options and restricted share units as part of its post-IPO incentive plans [1] Group 1: Stock Options - On September 18, 2025, the company granted a total of 6.7405 million stock options to 348 option grantees under the terms of its post-IPO stock option plan, pending acceptance by the grantees [1] Group 2: Restricted Share Units - On the same date, the company also granted 1.9115 million restricted share units to 196 grantees under the terms of its post-IPO restricted share unit plan, which is also subject to acceptance by the grantees [1]